article thumbnail

Pfizer, Flynn fined £70m in resurrected epilepsy drug pricing probe

pharmaphorum

Drugmakers Pfizer and Flynn Pharma have been fined £70 million ($84 million) by the UK Competition and Markets Authority (CMA) for overcharging the NHS for a widely-used epilepsy drug. ” The post Pfizer, Flynn fined £70m in resurrected epilepsy drug pricing probe appeared first on.

article thumbnail

UK biotech sees worst funding downturn since 2012

pharmaphorum

Indeed, Initial Public Offerings (IPOs) raised just £28 million – the worst annual haul since 2012 – and, during the entirety of last year, UK biotech raised just £1.8 There is global capital out there for us to attract, as well as finance in the City of London [that] we need to unlock, but competition is fierce.” billion in 2021.

Pharma 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pfizer and Flynn appeal £70m epilepsy drug fines in UK

pharmaphorum

Drugmakers Pfizer and Flynn Pharma have formally launched an appeal against a £70 million ($84 million) fine levied by the UK Competition and Markets Authority (CMA) for overcharging the NHS for a widely-used epilepsy drug. The CAT typically takes around nine months to deliver a verdict, although it can take longer in more complicated cases.

article thumbnail

Understanding the evidence used in drug product withdrawals

European Pharmaceutical Review

Between 1999 and 2001, it supported 17 percent of withdrawals, between 2002 and 2011, it supported 26 percent of withdrawals and by 2012 to 2016, 80 percent of withdrawals were supported by observational studies (cohort, case-control, or other epidemiologic design). Meta-analyses contributed least frequently (31.4 Lane S, Lynn E, Shakir S.

Medicine 116
article thumbnail

NICE unlocks use of Amarin’s Vazkepa in 425k NHS patients

pharmaphorum

Amarin first introduced its drug in the US as Vascepa in 2012, but only made it available in Europe last year, starting with a German launch last September. .” NHS England has estimated that between 25% and 35% of people having statin therapy have elevated triglycerides.

article thumbnail

The Fastest Growing Companies in Boston Hiring For Sales

CloserIQ

Founded 2012. Founded 2012. Founded 2012. Founded 2012. Founded 2012. Cybereason’s workplace culture is known to be fast-paced and competitive, with plenty of opportunities for learning. They are seeking to transform the automobile industry and are known for a fast-paced, collaborative work environment.

Sales 76
article thumbnail

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

2 It was first approved as Fulyzaq in December 2012 and in October 2016, Napo Pharmaceuticals launched the new brand, Mytesi. 14 Marketing authorisation In the UK, medicinal products placed on the market are required to have marketing authorisations in accordance with The Human Medicines Regulations 2012 (S.I. 2012/1916).

Marketing 103